What’s the Difference Between Sacroiliitis and Ankylosing Spondylitis?

Sacroiliitis and ankylosing spondylitis (AS) are closely related inflammatory conditions affecting the spine and pelvis—but they are not synonymous. Sacroiliitis refers specifically to inflammation of one or both sacroiliac (SI) joints—the large, weight-bearing joints that connect the sacrum to the iliac bones of the pelvis. It can arise from a variety of causes, including mechanical stress, infection (e.g., reactive arthritis triggered by gastrointestinal or genitourinary pathogens), trauma, or autoimmune disorders such as psoriatic arthritis or inflammatory bowel disease–associated spondyloarthritis.

In contrast, ankylosing spondylitis is a distinct, chronic systemic disease classified within the broader category of axial spondyloarthritis. While sacroiliitis is a hallmark feature—and often the earliest radiographic sign—of AS, the condition extends beyond the SI joints. AS involves progressive inflammation of the axial skeleton, particularly the spine and entheses (sites where tendons and ligaments attach to bone), leading over time to syndesmophyte formation, vertebral fusion, and potential spinal rigidity or kyphosis. Diagnosis of AS requires both clinical criteria—including chronic inflammatory back pain, morning stiffness lasting >30 minutes, and improvement with exercise—and objective evidence of sacroiliitis on imaging (MRI showing active inflammation or conventional radiography revealing structural damage).

Importantly, not all patients with sacroiliitis develop AS. Isolated sacroiliitis may remain stable or resolve spontaneously, especially when secondary to transient triggers like infection or overuse. Conversely, some individuals with early AS may have normal radiographs but show active bone marrow edema in the SI joints on MRI—a finding consistent with non-radiographic axial spondyloarthritis, a precursor stage to AS. Thus, sacroiliitis serves as a critical diagnostic clue and imaging biomarker, but its presence alone does not confirm AS; comprehensive clinical assessment, HLA-B27 testing (when appropriate), and longitudinal monitoring are essential for accurate classification and management.